Agile Therapeutics Inc (NASDAQ:AGRX) shares gapped up before the market opened on Tuesday . The stock had previously closed at $0.80, but opened at $0.90. Agile Therapeutics shares last traded at $0.95, with a volume of 6016 shares trading hands.
A number of research analysts recently weighed in on AGRX shares. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Agile Therapeutics in a research note on Friday, January 11th. Maxim Group started coverage on shares of Agile Therapeutics in a research note on Thursday, November 29th. They set a “buy” rating and a $3.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Agile Therapeutics presently has an average rating of “Buy” and a consensus target price of $3.33.
The company has a market cap of $31.12 million, a price-to-earnings ratio of -1.06 and a beta of 0.32.
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after acquiring an additional 18,038 shares in the last quarter. Acadian Asset Management LLC increased its stake in Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 226,255 shares during the last quarter. Renaissance Technologies LLC increased its stake in Agile Therapeutics by 54.3% in the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after acquiring an additional 430,907 shares during the last quarter. Finally, Fosun International Ltd bought a new position in Agile Therapeutics in the third quarter valued at $180,000. Institutional investors and hedge funds own 41.92% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2019/02/12/agile-therapeutics-agrx-shares-gap-up-to-0-90.html.
About Agile Therapeutics (NASDAQ:AGRX)
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Further Reading: What is a Derivative?
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.